Erythropoietin-mediated activation of aquaporin-4 channel for the treatment of experimental hydrocephalus von Rizwan Siddiqui, M., Attar, Furqan, Mohanty, Vineet, Kim, Kwang Sik, Shekhar Mayanil, C., Tomita, Tadanori

Volltext

Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors von Park, H., Shapiro, G.I., Gao, X., Mahipal, A., Starr, J., Furqan, M., Singh, P., Ahrorov, A., Gandhi, L., Ghosh, A., Hickman, D., Gallacher, P.D., Wennborg, A., Attar, E.C., Awad, M.M., Das, S., Dumbrava, E.E.

Volltext

516MO Phase I/II study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies von Park, H., Shapiro, G., Gao, X., Mahipal, A., Starr, J.S., Furqan, M., Singh, P., Ahrorov, A., Hickman, D., Gallacher, P., Attar, E., Awad, M., Das, S., Dumbrava, E.E. Ileana

Volltext

Phase 1/2 study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies von Dumbrava, Ecaterina Elena, Mahipal, Amit, Gao, Xin, Shapiro, Geoffrey, Starr, Jason S., Singh, Parminder, Furqan, Muhammad, Ahrorov, Afzal, Hickman, Denice, Gubits, Amy, Attar, Eyal C., Awad, Mark M., Das, Satya, Park, Haeseong

Volltext